Description:
FANCONI ANEMIA, COMPLEMENTATION GROUP C; FANCC
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
Hereditary Cancers
Engineered Cell Cultures |
| Class |
Syndromes with Increased Chromosome Breakage |
|
Cell Type
|
Fibroblast
|
|
Transformant
|
Untransformed
|
|
Family Member
|
1
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Clinical summary/Case history
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| PDL at Freeze |
4.97 |
| Passage Frozen |
21 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase,Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
| |
| Remarks |
Clinically affected; line PD331.F RV:FANNC puro; corrected line derived by retroviral infection of the line PD331.F (GM16754) complementation group C, with the gene that encodes FANCC. |
| Passage Frozen |
21 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
3% |
| Medium |
MEM (Eagle) Alpha Modification with nucleosides/Dulbecco Modified Eagles Medium (high glucose), 1:1 mixture with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Substrate |
Gelatin |
| Supplement |
- |
|
|